Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Scand J Rheumatol ; 52(4): 374-384, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-35659437

RESUMO

OBJECTIVES: : Knowledge of the correspondence between clinical ICD diagnoses and classification criteria fulfilment is crucial to interpret studies identifying cases via ICD codes. We assessed the degree to which patients registered with ICD-10 diagnoses of psoriatic arthritis (PsA) in the Swedish National Patient Register (NPR) fulfil established PsA classification criteria. METHOD: Four hundred patients with at least one outpatient visit to one of five rheumatology or internal medicine departments (three university/two county departments across Sweden) in 2013-2015, with a main ICD-10 diagnosis of PsA (L40.5, M07.0-M07.3), were randomly selected (80 cases/site). Through a structured medical record review, positive predictive values (PPVs) for fulfilment of the following classification criteria were assessed: CASPAR, Moll and Wright, Vasey and Espinoza, and modified ESSG criteria for PsA. A subset analysis regarding CASPAR fulfilment was also performed among cases with available rheumatoid factor and peripheral X-ray status (central CASPAR items; n = 227). RESULTS: Of the 400 patients with a main ICD-10 diagnosis of PsA, 343 (86%) fulfilled at least one of the four PsA classification criteria. PPVs for the different criteria were: CASPAR 69% (82% in the subset analysis), Moll and Wright 51%, Vasey and Espinoza 76%, and modified ESSG 64%. Overall, only 6.5% of the 400 PsA diagnoses were judged as clearly incorrect by the medical record reviewers. CONCLUSION: The validity of rheumatologist-made, clinical ICD-10 diagnoses for PsA in the Swedish NPR is good, with PPVs of 69-82% for CASPAR fulfilment and 86% for meeting any established PsA classification criteria.


Assuntos
Artrite Psoriásica , Humanos , Artrite Psoriásica/diagnóstico , Suécia , Reumatologistas , Valor Preditivo dos Testes , Fator Reumatoide
2.
Scand J Rheumatol ; 51(1): 10-20, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33755519

RESUMO

Objective: To determine whether a family history of spondyloarthritis (SpA) is associated with clinical presentation at the start of tumour necrosis factor inhibitor (TNFi) treatment, or predictive of TNFi drug survival and treatment response in patients with SpA.Method: Family history of SpA in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), and undifferentiated SpA (uSpA) from the Swedish Rheumatology Quality register starting a TNFi as their first biologic in 2006-2018 was assessed through national registers. Clinical characteristics at treatment start were compared by family history status. We used Cox regression to estimate hazard ratios for drug discontinuation, and analysed treatment response at 3 and 12 months with linear regression. Multiple imputation was used to address missing data.Results: We included 9608 patients. Patients with family history had an earlier age at onset and longer disease duration at TNFi treatment start, but did not differ regarding disease activity and presence of SpA manifestations. Hazard ratios for drug discontinuation were 1.08 [95% confidence interval (CI) 0.89-1.31] for AS patients with a family history of AS, 1.02 (95% CI 0.89-1.18) for PsA patients with a family history of PsA, and 1.11 (95% CI 0.85-1.45) for uSpA patients with a family history of uSpA, after adjusting for demographic, socioeconomic, and SpA-related factors. Treatment response at 3 and 12 months was similar between groups.Conclusion: Family history of SpA was not found to be associated with clinical presentation at the start of TNFi treatment, nor was it associated with drug survival or treatment response in SpA patients starting a first TNFi.


Assuntos
Antirreumáticos , Espondilartrite , Espondilite Anquilosante , Antirreumáticos/uso terapêutico , Estudos de Coortes , Humanos , Espondilartrite/tratamento farmacológico , Espondilite Anquilosante/tratamento farmacológico , Suécia/epidemiologia , Resultado do Tratamento , Inibidores do Fator de Necrose Tumoral/uso terapêutico , Fator de Necrose Tumoral alfa
4.
Med Biol ; 58(2): 112-6, 1980 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7432007

RESUMO

Haemoglobin (Hb) and transferrin (Tf) types were determined in 760 Finnsheep and correlated with the reduced glutathione (GSH) levels of packed erythrocytes. The gene frequencies of the two haemoglobin alleles A and B were: HbA = 0.748 and HbB = 0.252. Five transferrin alleles were found: A, B, C, D and E, with gene frequencies of 0.056, 0.226, 0.620, 0.075 and 0.023, respectively. The Hb B group had significantly higher GSH levels and lower haematocrit values than heterozygotes (Hb AB) and homozygote (Hb AA). There was no significant difference in GSH concentration among the haemoglobin types in lambs. Erythrocyte glutathione levels of Tf BC ewes were significantly higher than the levels in sheep with other transferrin types, whereas young lambs of Tf AB types had the highest GSH levels. The significance of these findings is discussed.


Assuntos
Glutationa/sangue , Hemoglobinas/genética , Ovinos/sangue , Transferrina/genética , Alelos , Animais , Eritrócitos/análise , Feminino , Frequência do Gene , Hematócrito , Transferrina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA